Indefinite Delivery Contract 75N93021D00010
Award Date
10/15/20
Last Date to Order
10/14/27
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Southern Research Institute
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
AN81 - R&D- Medical: Aids Research (Basic Research)
Federal Contract Vehicle
Pricing Type
Cost Plus Fixed Fee
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Sri International to provide preclinical development support for candidate products and drug development activities. The $107.3M contract has a 7-year period of performance from October 2020 to October 2027. The contract encompasses a broad scope of work, including in vitro testing and screening, small...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a single-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Lovelace Biomedical Research Institute to provide preclinical development support for candidate products and drug development activities for HIV, hepatitis, and tuberculosis. The 7-year, $107.3 million contract covers a range of services across seven task areas, including in vitro screening,...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract worth up to $107,274,471 to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B and C, and tuberculosis. This multiple-award IDIQ contract has a 7-year period of performance from October 2020 to October 2027. The scope...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded this multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B, hepatitis C, and tuberculosis. The $107.3 million contract has a 7-year period of performance and encompasses seven task areas, including in vitro testing, synthesis of...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, awarded a single-award Indefinite Delivery Contract valued up to $146,300,000 to Southern Research Institute, a non-profit research organization, to develop and employ animal and animal replacement models of infectious diseases. The contract will support screening, product evaluation, and eventual clinical evaluation of vaccines, therapeutics, and...
The National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) within the Department of Health and Human Services, has awarded a $107,274,471 multiple-award indefinite-delivery/indefinite-quantity (IDIQ) contract for Preclinical Services for HIV Therapeutics. The prime contractor, Starks Associates Inc., is a for-profit subchapter S corporation that will provide a range of preclinical development support services, from initial product...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded this $107,274,471 Indefinite Delivery/Indefinite Quantity (IDIQ) contract to the University of North Carolina at Chapel Hill (UNC-CH) to provide preclinical development support for candidate products and drug development activities related to infectious diseases like HIV, hepatitis, and tuberculosis. The contract encompasses a wide range of services including in...
The National Institute of Allergy and Infectious Diseases has awarded an indefinite delivery contract with a potential value of $107,274,471 to multiple prime contractors to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Task orders will be issued under seven task areas, including in vitro testing, synthesis of therapeutic agents, small animal...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. The total potential value of the IDV is $107,274,471 over seven years ending October 2027. Task orders have been issued under several areas. Lovelace Biomedical Research Institute received a $18,397 order to develop...
This Indefinite Delivery Contract (IDC) was awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Southern Research Institute, a non-profit organization. The contract, valued at up to $24,293,824, is for an "In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides" and does not have a set-aside designation. Under this IDC, Southern Research Institute is providing a range of services, including optimization and...